-
公开(公告)号：US20180280392A1
公开(公告)日：2018-10-04
申请号：US15524394
申请日：2015-11-06
Inventor： Jin ZENG , Ruijun WANG , Xiaolei WANG
IPC: A61K31/519 , A61K9/20 , A61K9/28 , A61K9/48
Abstract: Disclosed is a pharmaceutical preparation having 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazine-1-yl-pyridine-2-yl amino group)-8H-pyrido[2,3-d]pyrimidine-7-one or salt thereof as an active ingredient, the salt comprising hydrochloride or isethionate, and the dosage form thereof comprising tablets and capsules both having good stability and excellent dissolution performance.
-
公开(公告)号：US20180282300A1
公开(公告)日：2018-10-04
申请号：US15524694
申请日：2015-11-09
Inventor： Hongwei TANG , Changan SUN , Ruijun WANG , Hengli YUAN
IPC: C07D401/12
CPC classification number: C07D401/12 , A61K31/4439 , C07B2200/13
Abstract: The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1. The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development.
